Featured Genomics Experts

Dr. James Utley is a pioneering scientist at the forefront of cellular therapy, AI, and data science. A Johns Hopkins-educated Immunohematology expert and Certified Advanced Biotherapies Professional (CABP), he also holds advanced certifications in data science and machine learning. While serving as Technical Director at a major healthcare organization, Dr. Utley oversaw more than 150,000 successful cellular transfusions and spearheaded advancements that significantly improved patient outcomes. This experience included leading initiatives for the Department of Defense, where he revolutionized cellular transfusion practices. His innovative approach is further exemplified by his FDA-approved work and numerous publications in leading scientific journals. Dr. Utley is also known for his bold, hands-on approach to research, embodying the spirit of a "biohacker" by pushing the boundaries of CRISPR and genetic engineering through self-experimentation. This unique blend of rigorous scientific training and unconventional methods has earned him the moniker "the pirate" within the biohacker community.

Founder & CEO of Genbounty - AI safety & compliance testing. Genbounty is a an AI safety testing hub and provider of EU AI Act compliance and certification. About me AppSec SME, AI Engineer, Developer | BSc, MBA, PRINCE2, CompTIA+, CISSP

With a PhD in molecular genetics and as a specialist in data science, Céline Chantry-Darmon has over twenty years of experience in biomedical research and complex data analysis. As Scientific Director at Tekkare, she works on developing trustworthy artificial intelligence for healthcare. She is also committed to promoting inclusive and responsible artificial intelligence, and to advancing women in science and technology.

Clinical trial management of two stem cell clinical trials. I have a passion for data science analytics and rigorous pattern-seeking. I believe in leading from the front and making sure the team is well taken care of. *Managing 2 stem cell clinical trials, NCT02838316 and NCT05421689*30 peer-reviewed publications.*>12,000 citations.*2 provisional patents.*Co-founded startup.*Co-developed departmental leadership program.*Strong track record of grant funding and collaboration building.* Associated Editor for two flagship scientific journals (Stem Cells, Journal of Extracellular Biology).GOOGLE SCHOLAR PROFILEhttps://scholar.google.com/citations?user=3uQtjEEAAAAJ&hl=en

Ryan Farmer is the founder of My Peptide Match, a consumer education site that helps people make sense of GLP-1 medications and the fast-changing peptide landscape. He focuses on simplifying complex topics—like real-world pricing, treatment pathways, sourcing differences, and what questions to ask—so readers can make more informed decisions with their clinician. Ryan tracks emerging trends across weight-loss peptides, compounding and telehealth access, and the economics that shape what consumers actually pay. He’s available to comment on GLP-1 and peptide cost comparisons, patient decision-making, and the broader market shifts driving demand. He also publishes practical reference tools, including a peptide calculator and dosage guide, to support clearer conversations between consumers and providers.

Founder of PeptideLeads, a patient generation agency built specifically for peptide therapy clinics. We deliver qualified patients at $50 each with no retainer and no ad spend from the clinic. Built on a proprietary database of every peptide clinic in the US.

Hey network! I'm Anurag Srivastav Thammera, a graduate of KL University with a deep-rooted passion for entrepreneurship and emerging technology. I have always been driven by the belief that AI can fundamentally transform the way humans live and work — and that belief has shaped every step of my journey, pushing me far beyond the classroom toward building real solutions at the intersection of intelligence and impact. I am the Founder & CTO of KrAIonyX, an AI startup focused on developing large language models, agentic systems, and intelligent products that act as capable human assistants. At KrAIonyX, I lead the vision of deploying high-assurance AI across high-potential sectors — particularly EdTech and HealthTech — where agentic AI can meaningfully improve outcomes for people. I bring hands-on experience building real-world AI products, including KrAiGita, a flagship product from the KrAIonyX ecosystem. My work sits at the frontier of where cutting-edge AI research meets practical, human-centered impact. If you're someone who builds with purpose, thinks beyond the ordinary, and wants to shape the future with ideas rather than just effort — let's connect. Always open to conversations with like-minded founders, builders, and visionaries who believe the best is still yet to be created.

I am a Bioinformatician with extensive experience of analyzing Genomics and Transcriptomics data from Next Generation Sequencing Platforms. I enjoy designing, implementing and automating computational pipelines for Biological Data Analysis using multiple programming languages. I also possess over three years of experience working in wet lab with several Molecular Biology tools. I have worked as teaching assistant for both undergrads and grad students.I enjoy solving problems independently as well as by being part of a collaborative inter-disciplinary team.

Len May is a Certified Medical Cannabis Specialist with 25 years of cannabis- related experience. He was president of the Cannabis Action Network, and a lifetime board member of the California Cannabis Association as well as the Association of Cannabis Specialists. May has a Masters of Medical Cannabis and an Endocannabinoid Formulation Specialist Certification from the Institute for the Advancement of Integrative Medicine. Currently, Len May is CEO and Co-Founder of Endocanna Health, a Bio-Science Technology company and the parent company of Endo DNA. Mr. May is an accomplished public speaker having presented on these topics on some of the world’s most prestigious stages in his mission to help educate the population about the healing powers personalized of cannabis.

Dr. Giovanni Abbadessa is a seasoned oncology developer with over 20 years of experience in advancing innovative therapies across biotech, pharmaceutical, and nonprofit sectors. He joined ModeX Therapeutics as Chief Medical Officer, where he leads the development of the company’s multispecific biologics for cancer and infectious diseases. Prior to ModeX, Dr. Abbadessa was Vice President and Head of Oncology Early Development at Sanofi, where he spearheaded the clinical development of 16 experimental oncology drugs, guiding them from first-in-human studies through to Phase 2 trials. He established a dynamic team of 25 professionals and played a pivotal role in in-licensing 10 clinical assets. Dr. Abbadessa contributed to strategic oversight across multiple portfolios, including Phase 3 assets and partnerships, and collaborated with Investor Relations on oncology-focused initiatives.

I'm Neil, the CEO of Phyla. Our patented phage technology kills acne without harming your skin microbiome...no side effects. Phages are the most abundant micro-organism on the planet, and they keep the planet healthy by killing harmful bacteria. Phages are also found on healthy skin. Phyla's serum gets to the root cause of acne, the c.acnes bacteria, clearing your hormonal, cystic and teenage acne.We hear from so many customers who've tried Accutane, Antibiotics and Benzoyl Peroxide to no success until they used Phyla. Acne sucks and it's heartwarming to hear their success stories.I was previously the COO at GenoPalate, a nutrigenomics start-up that personalized nutrition based on DNA analysis. I spent a decade at Colgate-Palmolive, building brands and driving growth across Latin America, Asia and the US. I have an MBA from Kellogg and a BS in Finance from Boston College.

At Crystal Ball, we've developed an innovative solution to address the challenge of…

Ilya J. Finkelstein, PhD is a Professor of Molecular Biosciences at The University of Texas at Austin specializing in gene editing, biophysics, and biotechnology. He has published 100+ peer-reviewed papers, holds multiple patents, and has served as an expert witness and technical consultant. His work appears frequently in scientific and popular press.

Cancer researcher specializing in using computational methods to analyze complex biological data and understand how tumors and cancer treatments affect the tissue microenvironment. My current research focuses on leveraging cutting-edge omics methods, such as spatial omics and single-cell sequencing, to understand the connection between immune aging and blood cancers.

I'm James, a digital marketing veteran since 2000, building successful strategies that elevate your websites into true industry leaders when it comes to search. I've had amazing success with companies from many sectors. From turning one-man business into industry leaders, to turning offline industry giants into companies that dominate online for thousands of search terms. I'm able to help any member of the C-suite to understand what is needed to be successful in their industry - and to get them there, too. My aim is to support those people that have experienced mediocre, or average experiences with SEO agencies. I like to show people that strategies are always more simple than you think - but that hard work is still required. Send me a DM if you would like some help.

Sergio Occhipinti, PhD, is a medtech founder and scientist dedicated to advancing urine-based diagnostics for prostate cancer. As CEO of NIB Biotec since 2017, he has driven the company’s scale-up, closing two investment rounds and obtaining competitive public grants, enabling faster R&D, validation, and market access for innovative in vitro diagnostics. Sergio earned his PhD in Molecular Medicine at the University of Turin and brings 15+ years of preclinical and clinical research experience. His work has focused on urinary liquid biopsy, immuno-oncology, and the design of novel clinical protocols. He is an inventor on patents related to prostate cancer biomarkers and diagnostics, underscoring his commitment to rigorous, translational science. To bridge lab and market, he completed a Master in Project Management of Multimedia for Communication and SDA Bocconi’s Impact Your Talent – Impactful Entrepreneurship & Finance, with additional training in social entrepreneurship and impact investing. His work in innovation and tech transfer has been recognized by international programs and awards.

Panos Papadiamantis is an engineer and inventor who is dedicated to helping people live longer and better by leveraging the two most potent drugs in nature, nutrition, and exercise. He started his academic career at the National Technical University of Athens and then moved to the United States to continue to pursue a graduate degree at the Stanford School of Engineering. During his stint at Stanford, he worked in the Center of International Security and Collaboration alongside Siegfried Hecker, former director of the Los Alamos National Laboratory, and William Perry, former Minster of Defence of the United States, in conducting research and risk analysis on nuclear technology and its implications on national security. Following his studies at Stanford, he worked as a product manager in IT infrastructure companies in Silicon Valley but was always passionate about health and envisioned developing technologies that would prolong the quality and length of life. Hence, he jumped on board when his cofounder and friend approached him about developing the first affordable breath analysis device to analyze human metabolism with clinical precision. Together, they co-founded PNOĒ, one of the most rapidly evolving precision health technology companies trusted by thousands of health professionals, athletes, research centers, and longevity pioneers, including UCLA, MIT, Red Bull, Inbody, Chicago Cubs, and many more. Through his entrepreneurial endeavors, he became a Y Combinator alumni, and in 2015 joined Forbes 30 under 30.